Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05464082 · ClinicalTrials.gov registry record · Phase 2
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
A Phase 2 study of Breast Cancer Recurrent, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05464082 is a Phase 2 study of Breast Cancer Recurrent that is actively recruiting participants, run by University of Utah. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05464082, a Phase 2 study of Breast Cancer Recurrent, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
Conditions Studied
Interventions
- OTHER Functional Precision Oncology
Study Locations (1)
Utah
- Huntsman Cancer Institute at University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-01-06 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05464082
The ClinicalTrials.gov registry entry for NCT05464082 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Recurrent appearing as the primary indexed condition, and to 1 intervention - of which Functional Precision Oncology is the first listed.
NCT05464082 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT05464082 about?
NCT05464082 is a clinical study titled "Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC". This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
What is the current status of trial NCT05464082?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-01-06. Estimated completion is 2028-09-30.
What conditions does trial NCT05464082 study?
This clinical trial studies the following conditions: Breast Cancer Recurrent.
What interventions are being tested in trial NCT05464082?
The interventions under investigation include: Functional Precision Oncology (OTHER).
Who is sponsoring clinical trial NCT05464082?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05464082 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.